
Quality of life after extended pelvic exenterations Cibula D.*1, Lednický Š.1, Höschlová E.2, Sláma J.1, Wiesnerová M.3, Mitáš P.4, Matějovský Z.5, Schneiderová M.6, Dundr P.7, Němejcová K.7, Burgetová A.⁸, Zámečník L.⁹, Vočka M.¹⁰, Kocián R.¹, Frühauf F.¹, Dostálek L.¹, Fischerová D.¹, Borčinová M.¹

¹Gynaecologic oncology centre, First Faculty of Medicine, Charles University (CU) and General University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ³Institute of Biostatistics and Analyses, Masaryk University, Brno, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second surgical clinic, First Faculty of Arts, CU, CZ; ⁴Second su Faculty of Medicine, CU and GUH, CZ; ⁵Department of Orthopaedics, First Faculty of Medicine, CU and Hospital Kralovske Vinohrady, CZ; ⁷Department of Pathology, First Faculty of Medicine, CU and GUH, CZ; ⁸Department of radiology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and GUH, CZ; ¹⁰Department of Oncology, First Faculty of Medicine, CU and CU and CU and CU and CU and CU

; No conflicts of interest to declare. *email:



A: Pelvic exenteration (black line: total, green line: anterior, blue line: posterior) adopted [4];

B: Additional pelvic side wall structures resected during extended pelvic exenteration (green: bones; pink: muscles; yellow: nerves; red: vessels)

ESMO GYNAECOLOGICAL CANCERS

EPE procedures offer a potentially curative treatment option for patients with recurrent pelvic tumour invading into pelvic wall structures without negative trade-off further compromising longterm life aspects.

Funding: This work was supported by Charles University in Prague (UNCE 204065 and COOPERATIO) and General University Hospital (MH CZ – DRO-VFN64165). The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the abstract; or in the decision to publish the results.

Health-related quality of life

Table 1 EORTC QLQ 30, EORTC QLQ-CX24 – main results

Functio Global Physica Role fur Emotio Cogniti Therap Would Therapy Therapy

QoL assessment was performed using EORTC QLQ-C30, EORTC CX-24, and QOLPEX questionnaires specifically developed for patients after (E)PE.

The protocol of the study was approved by the institutional review board. Informed consent forms were obtained from all living patients participating in the QoL surveys.





GENERAL UNIVERSITY HOSPITAL IN PRAGUE



FIRST FACULTY

Thirty-one survivors participated in the QoL surveys (20 PE, 11 EPE). No significant differences were observed in global health status (P=0.951) or in any of the functional scales. The groups were not differing in therapy satisfaction (P=0.502), and expressed similar, high willingness to undergo treatment again (P=0.317) (Table 1).

| | Pelvic exenteration | | Extended pelvic exenteration | | |
|-------------------|---------------------|-------------------|---------------------------------|---------------|---------|
| | N | Mean (SD) | N | Mean (SD) | P-value |
| onal Scales (high | er value | | | | |
| Health Status | 20 | 62.9 (19.75) | 11 | 64.5 (21.36) | 0.951 |
| al functioning | 20 | 67.2 (23.92) | 11 | 73.0 (19.62) | 0.583 |
| Inctioning | 20 | 57.8 (40.28) | 11 | 60.9 (31.84) | 0.951 |
| onal functioning | 20 | 75.2 (20.64) | 11 | 81.2 (18.34) | 0.427 |
| ive functioning | 20 | 87.8 (16.78) | 11 | 82.3 (11.60) | 0.157 |
| y Assessment (h | igher va | lue = higher sati | sfactio | n) | |
| Undergo Again | 20 | 83.8 (28.42) | 11 | 72.7 (28.40) | 0.317 |
| y Satisfaction | 20 | 90.0 (18.85) | 11 | 86.36 (17.19) | 0.502 |
| y Assessment | 20 | 82.5 (15.75) | 11 | 71.9 (15.03) | 0.066 |
| | | | | | |

SD: standard deviation.

MATERIALS AND METHODS

Data from patients who underwent PE (42) or EPE (32) between 2004 to 2019 at a single tertiary gynaeoncology centre in Prague were analysed. Disease-free survival (DFS) was defined as the interval from surgery to the diagnosis of recurrence or progression of the disease. Overall survival (OS) was defined as the interval from surgery to death. OS and DFS were estimated using the Kaplan–Meier method and differences were calculated using the log-rank test.

[1] Cibula D. Elsevier 2018. p. 193-206. ISBN 9780323428781

[2] Hockel M. Am J Obstet Gynecol. 1999;180:306-12.

[3] Caceres A, Mourton SM, et al. Int J Gynecol Cancer. 2008;18:1139-44.

[4] Martin R, Hardy K, Kumar P. Gastrointestinal Nursing. 2020;18:22-5.

47P